The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Oral Azole Drugs as Systemic Antifungal Therapy
Abstract
The oral azole drugs--ketoconazole, fluconazole, and itraconazole--represent a major advance in systemic antifungal therapy. Among the three, fluconazole has the most attractive pharmacologic profile, including the capacity to produce high concentrations of active drug in cerebrospinal fluid and urine. Ketoconazole, the first oral azole to be introduced, is less well tolerated than either fluconazole or itraconazole and is associated with more clinically important toxic effects, including hepatitis and inhibition of steroid hormone synthesis. However, ketoconazole is less expensive than fluconazole and itraconazole--an especially important consideration for patients receiving long-term therapy. All three drugs are effective alternatives to amphotericin B and flucytosine as therapy for selected systemic mycoses. Ketoconazole and itraconazole are effective in patients with the chronic, indolent forms of the endemic mycoses, including blastomycosis, coccidioidomycosis, and histoplasmosis; itraconazole is also effective in patients with sporotrichosis. Fluconazole is useful in the common forms of fungal meningitis--namely, coccidioidal and cryptococcal meningitis. In addition, fluconazole is effective for selected patients with serious candida syndromes such as candidemia, and itraconazole is the most effective of the azoles for the treatment of aspergillosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
Hospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831
Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679
Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.1993.03500120051025 · Cited by 664
Grant, S. M., & Clissold, S. P. (1990) · Drugs · doi:10.2165/00003495-199039060-00006 · Cited by 661
The use of ketoconazole as an inhibitor of steroid production
Oates, J. A., Wood, A. J. J., & Sonino, N. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709243171307 · Cited by 395
Self-citationFisher, M. A., Shen, S. H., Haddad, J., & Tarry, W. F. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.9.1443 · Cited by 81
Research works printed but not linked: 112
- 10.1093/clinids/12.2.308 · DOI · Paper page
- Joly V, 1992, Antimicrob Agents Chemother, 36, 1799, 10.1128/AAC.36.9.1799 · DOI
- Van den Bossche H, 1983, Biochem Soc Trans, 11, 665, 10.1042/bst0110665 · DOI · Paper page
- Sud IJ, 1979, Antimicrob Agents Chemother, 16, 660, 10.1128/AAC.16.5.660 · DOI
- 10.1080/00362178085380351 · DOI
- 10.1093/clind/15.6.1003 · DOI · Paper page
- 10.1210/jcem-57-4-732 · DOI · Paper page
- 10.1172/JCI110903 · DOI · Paper page
- 10.1001/archinte.144.11.2150 · doi:10.1001/archinte.144.11.2150
- 10.1002/ddr.430080133 · DOI
- Hanger DP, 1988, Antimicrob Agents Chemother, 32, 646, 10.1128/AAC.32.5.646 · DOI
- 10.2165/00003088-198308010-00002 · DOI · Paper page
- 10.2165/00003495-198937030-00003 · DOI · Paper page
- Saag MS, 1988, Antimicrob Agents Chemother, 32, 1, 10.1128/AAC.32.1.1 · DOI · Paper page
- 10.1007/BF00558308 · DOI · Paper page
- Hardin TC, 1988, Antimicrob Agents Chemother, 32, 1310, 10.1128/AAC.32.9.1310 · DOI · Paper page
- Barone JA, 1993, Antimicrob Agents Chemother, 37, 778, 10.1128/AAC.37.4.778 · DOI · Paper page
- Tucker RM, 1988, Antimicrob Agents Chemother, 32, 369, 10.1128/AAC.32.3.369 · DOI · Paper page
- Humphrey MJ, 1985, Antimicrob Agents Chemother, 28, 648, 10.1128/AAC.28.5.648 · DOI · Paper page
- Brammer KW, 1991, Drug Metab Dispos Biol Fate Chem, 19, 764
- Hostetler JS, 1992, Antimicrob Agents Chemother, 36, 477, 10.1128/AAC.36.2.477 · DOI
- Blum RA, 1991, Ann Intern Med, 114, 755, 10.7326/0003-4819-114-9-755 · DOI · Paper page
- 10.1016/S0190-9622(88)70037-7 · DOI · Paper page
- Lazar JD, 1990, Semin Oncol, 17, 14
- 10.1093/jac/21.1.93 · DOI
- Boelaert J, 1988, Antimicrob Agents Chemother, 32, 1595, 10.1128/AAC.32.10.1595 · DOI
- Toon S, 1990, Br J Clin Pharmacol, 29, 221, 10.1111/j.1365-2125.1990.tb03623.x · DOI
- 10.2165/00003088-199018060-00006 · doi:10.2165/00003088-199018060-00006
- Hector RF, 1990, Antimicrob Agents Chemother, 34, 448, 10.1128/AAC.34.3.448 · DOI
- 10.1159/000238951 · DOI
- Galgiani JN, 1987, Antimicrob Agents Chemother, 31, 1867, 10.1128/AAC.31.12.1867 · DOI
- Galgiani JN, 1993, Antimicrob Agents Chemother, 37, 2517, 10.1128/AAC.37.12.2517 · DOI
- Fan-Havard P, 1991, Antimicrob Agents Chemother, 35, 2302, 10.1128/AAC.35.11.2302 · DOI
- 10.1093/jac/31.4.463 · DOI · Paper page
- 1993, Antimicrob Agents Chemother, 37, 2443, 10.1128/AAC.37.11.2443 · DOI
- Cameron ML, 1993, Antimicrob Agents Chemother, 37, 2449, 10.1128/AAC.37.11.2449 · DOI
- Terrell CL, 1992, Mayo Clin Proc, 67, 69, 10.1016/S0025-6196(12)60281-X · DOI
- 10.1093/jac/26.4.561 · DOI · Paper page
- Lewis JH, 1984, Gastroenterology, 86, 503, 10.1016/S0016-5085(84)80021-9 · DOI · Paper page
- 10.1001/archinte.151.5.1020 · doi:10.1001/archinte.151.5.1020
- 10.1056/NEJM199203193261203 · DOI · Paper page
- 1985, Ann Intern Med, 103, 861, 10.7326/0003-4819-103-6-861 · DOI
- Sharkey PK, 1991, Antimicrob Agents Chemother, 35, 707, 10.1128/AAC.35.4.707 · DOI
- Phillips P, 1987, Antimicrob Agents Chemother, 31, 647, 10.1128/AAC.31.4.647 · DOI
- 10.1093/clinids/14.1.165 · DOI · Paper page
- Piscitelli SC, 1991, Antimicrob Agents Chemother, 35, 1765, 10.1128/AAC.35.9.1765 · DOI
- 10.1093/clinids/12.Supplement_3.S327 · DOI · Paper page
- Apseloff G, 1991, J Clin Pharmacol, 31, 358, 10.1002/j.1552-4604.1991.tb03718.x · DOI
- 10.1056/NEJM198412273112606 · DOI
- Kramer MR, 1990, Ann Intern Med, 113, 327, 10.7326/0003-4819-113-4-327 · DOI
- 10.1001/jama.264.21.2788 · doi:10.1001/jama.264.21.2788 · Paper page
- 10.1001/jama.269.12.1513 · DOI
- 10.1093/clind/16.3.400 · DOI
- Lopez-Gil JA, 1993, Ann Pharmacother, 27, 427, 10.1177/106002809302700405 · DOI
- 10.1038/clpt.1987.179 · DOI
- 10.1038/clpt.1985.42 · DOI
- Back DJ, 1991, Br J Clin Pharmacol, 32, 624, 10.1111/j.1365-2125.1991.tb03963.x · DOI · Paper page
- 10.1001/archinte.148.12.2642 · DOI · Paper page
- 10.1001/archinte.149.10.2226 · doi:10.1001/archinte.149.10.2226 · Paper page
- 10.1093/clinids/14.4.875 · DOI · Paper page
- 10.1093/clinids/14.Supplement_1.S106 · DOI
- 10.1016/0002-9343(89)90475-0 · DOI · Paper page
- 10.1016/0190-9622(90)70263-H · DOI · Paper page
- Bradsher RW, 1985, Ann Intern Med, 103, 872, 10.7326/0003-4819-103-6-872 · DOI
- 10.1016/0002-9343(92)90575-V · DOI · Paper page
- Pappas PG, Bradsher RW, Chapman SW, et al. Fluconazole in the treatment of blastomycosis. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 29-October 2, 1991. Washington, D.C.: American Society for Microbiology, 1991:292. abstract.
- 10.1093/infdis/164.6.1232 · DOI
- 10.1093/clinids/14.4.952 · DOI
- 10.1093/clinids/14.Supplement_1.S161 · DOI · Paper page
- Rex JH, Bennett JE, Sugar AM, et al. Fluconazole vs. amphotericin B for treatment of candidemia: results of a randomized multicenter trial. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, October 17-20, 1993. Washington, D.C.: American Society for Microbiology, 1993:267. abstract.
- 10.1016/0002-9343(91)90005-I · DOI · Paper page
- 10.1016/0002-9343(91)90006-J · DOI · Paper page
- 10.1093/clind/16.5.677 · DOI · Paper page
- 10.1016/0002-9343(88)90143-X · DOI
- 10.1016/0002-9343(90)90339-F · DOI · Paper page
- 10.1378/chest.97.3.666 · DOI
- 10.1093/clinids/14.Supplement_1.S68 · DOI
- Galgiani JN, 1993, Ann Intern Med, 119, 28, 10.7326/0003-4819-119-1-199307010-00005 · DOI · Paper page
- Tucker RM, 1990, Ann Intern Med, 112, 108, 10.7326/0003-4819-112-2-108 · DOI
- 10.1056/NEJM199201093260202 · DOI · Paper page
- Berry AJ, 1992, Antimicrob Agents Chemother, 36, 690, 10.1128/AAC.36.3.690 · DOI
- Denning DW, Tucker RM, Hostetler JS, Gill S, Stevens DA. Oral itraconazole therapy of cryptococcal meningitis and cryptococcosis in patients with AIDS. In: Vanden Bossche H, Mackenzie DWR, Cauwenbergh G, Van Cutsem J, Drouhet E, Dupont B, eds. Mycoses in AIDS patients. New York: Plenum Press, 1990:305-24. · DOI
- 10.1097/00002030-199202000-00007 · DOI
- 10.1056/NEJM199102283240902 · DOI · Paper page
- 10.1093/clinids/2.4.643 · DOI
- Wheat LJ, Hafner RE, Wulfsohn M, Johnson J, Owens S. Itraconazole (Itra) is effective treatment for histoplasmosis in AIDS: prospective multicenter noncomparative trial. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Calif., October 10-14, 1992. Washington, D.C.: American Society for Microbiology, 1992:312. abstract.
- Wheat J, 1993, Ann Intern Med, 118, 610, 10.7326/0003-4819-118-8-199304150-00006 · DOI · Paper page
- 10.1016/0002-9343(83)90513-2 · DOI
- 10.1093/clinids/9.Supplement_1.S51 · DOI
- 10.1001/archderm.122.4.413 · doi:10.1001/archderm.122.4.413 · Paper page
- 10.1016/0002-9343(93)90280-3 · DOI
- Savani DV, 1987, Antimicrob Agents Chemother, 31, 6, 10.1128/AAC.31.1.6 · DOI · Paper page
- 10.1056/NEJM197907193010303 · DOI · Paper page
- 10.1056/NEJM198708063170602 · DOI · Paper page
- 10.1056/NEJM198909213211205 · DOI · Paper page
- Larsen RA, 1990, Ann Intern Med, 113, 183, 10.7326/0003-4819-113-3-183 · DOI · Paper page
- 10.1093/infdis/165.5.960 · DOI
- Milefchik E, Leal M, Hanbrich R, See D, Bozzette S, Larsen R. High dose fluconazole with and without flucytosine for AIDS-associated cryptococcal meningitis. In: Abstracts of the Ninth International Conference on AIDS/ Fourth STD World Congress, Berlin, Germany, June 6-11, 1993. Vol. I. Abstract book.
- 10.1097/00002030-199202000-00008 · DOI
- Aisner J, 1977, Ann Intern Med, 86, 539, 10.7326/0003-4819-86-5-539 · DOI · Paper page
- Burch PA, 1987, J Clin Oncol, 5, 1985, 10.1200/JCO.1987.5.12.1985 · DOI · Paper page
- 10.1378/chest.100.3.813 · DOI · Paper page
- 10.1016/S0140-6736(82)91874-8 · DOI
- 10.1093/infdis/152.6.1257 · DOI
- 10.1093/clinids/9.Supplement_1.S94 · DOI · Paper page
- 10.1016/0002-9343(87)90949-1 · DOI
- 10.1111/j.1439-0507.1989.tb02299.x · DOI · Paper page
- 10.1093/jac/27.3.369 · DOI
- Winston DJ, 1993, Ann Intern Med, 118, 495, 10.7326/0003-4819-118-7-199304010-00003 · DOI · Paper page
- 10.1056/NEJM199203263261301 · DOI · Paper page
- Slavin M, Bowden R, Osborne R, et al. Fluconazole prophylaxis in marrow transplant recipients: a randomized placebo-controlled double blind study. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Calif., October 10-14, 1992. Washington, D.C.: American Society for Microbiology, 1992:214. abstract.
- 10.1093/clinids/14.2.472 · DOI
Cited by
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038020-00002 · Cited by 508
Clinical and laboratory update on blastomycosis.
Saccente, M., & Woods, G. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00056-09 · Cited by 450
Metadata
- Authors
- Wood, A. J. J., Como, J. A., & Dismukes, W. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1994-01-27
- Volume
- 330
- Issue
- 4
- Pages
- 263-272
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1967866045
- Cited by
- 596
- References
- 7
- FWCI
- 45.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral Azole Drugs as Systemic Antifungal Therapy. https://app.cochat.ai/papers/10.1056/nejm199401273300407
- The paper
- Wood, A. J. J., Como, J. A., & Dismukes, W. E. (1994). Oral Azole Drugs as Systemic Antifungal Therapy. New England Journal of Medicine. https://doi.org/10.1056/nejm199401273300407
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.